Want to see WST full AI Analyst Report?
WST Stock Chart & Stats
$328.20
-$27.28(-7.67%)
At close: 4:00 PM EDT
$328.20
-$27.28(-7.67%)
Day’s Range― - ―
52-Week Range$223.83 - $386.00
Previous CloseN/A
Volume1.51M
Average Volume (3M)811.59K
Market Cap
$23.75B
Enterprise Value$25.48K
Total Cash (Recent Filing)$435.80M
Total Debt (Recent Filing)$312.10M
Price to Earnings (P/E)42.8
Beta0.75
Next Earnings
Oct 22, 2026EPS Estimate
2.18Next Dividend Ex-DateN/A
Dividend Yield0.26%
Share Statistics
EPS (TTM)7.87
Shares Outstanding70,375,760
10 Day Avg. Volume864,114
30 Day Avg. Volume811,594
Financial Highlights & Ratios
PEG Ratio33.99
Price to Book (P/B)6.26
Price to Sales (P/S)6.47
P/FCF Ratio42.42
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$402.75Price Target Upside22.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)8.92
Revenue Forecast (FY)$3.37B
Bulls Say, Bears Say
Bulls Say
Sustained High Profitability And Margin ExpansionWest’s consistently strong gross and operating margins reflect pricing power and a favorable shift toward higher‑value HVP Components and delivery devices. Durable margin expansion supports reinvestment capacity, underwriting of R&D and capex, and resilience to cyclical volume swings over the next 2–6 months.
Very Healthy, Low‑leverage Balance SheetExtremely low leverage and a large equity cushion provide financial flexibility to fund capex, M&A or buybacks while absorbing working‑capital swings from timing issues. This structural strength reduces solvency risk and preserves strategic optionality over the medium term.
Durable Demand From HVP Components And Biologics MixHigh‑value elastomer and delivery products tied to biologics and GLP‑1 therapies drive recurring, long‑lifecycle sales with high customer qualification barriers. Strong win rates and mix shift to premium products support sustainable top‑line and margin improvement beyond short cycles.
Bears Say
Modest Overall Revenue Growth NormalizationWhile 2026 shows pockets of strong organic growth, multi‑year top‑line growth has normalized from earlier peaks. Slower aggregate revenue expansion constrains leverage benefits on fixed costs and limits upside from operating‑leverage versus periods of stronger secular growth.
Weaker Free Cash Flow Conversion And Timing PressureLower FCF conversion and episodic operating cash timing (AR build from cyber recovery) reduce near‑term cash available for buybacks or faster deleveraging. Continued capex guidance and working‑capital variability could pressure liquidity and capital allocation flexibility over coming quarters.
Segment Concentration And Contract Exit Risks In West VantageDependence on a few large contracts and recent contract exits create near‑term revenue troughs and comparability headwinds. Segment concentration increases sensitivity to customer‑specific decisions, which can amplify quarter‑to‑quarter volatility despite overall durable demand in HVP businesses.
West Pharmaceutical Services News
WST FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
West Pharmaceutical Services, Inc. lowest stock price was $223.83 and its highest was $386.00 in the past 12 months.
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is $23.75B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Oct 22, 2026 which is in 83 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Jul 23, 2026. The company reported $2.37 earnings per share for the quarter, beating the consensus estimate of $2.082 by $0.288.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. pays a Quarterly dividend of $0.22 which represents an annual dividend yield of 0.26%. See more information on West Pharmaceutical Services, Inc. dividends here
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 2.18.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
West Pharmaceutical Services, Inc. has 70,375,760 shares outstanding.
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $2.37 in its last earnings report, beating expectations of $2.082. Following the earnings report the stock price went down -0.818%.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in WST
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$402.75 (22.71% Upside)
$402.75 (22.71% Upside)
Blogger Sentiment
Bullish
WST Sentiment 89%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 925.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 16.3%
Last 30 Days ▲ 16.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.98%
12-Months-Change
Fundamentals
Return on Equity
0.26%
Trailing 12-Months
Asset Growth
3.13%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) is a healthcare and life sciences company that develops and manufactures packaging and delivery components for injectable drugs and other biologics. The company’s core offerings include elastomer-based components (such as stoppers and seals) used in vials and prefilled syringes, advanced containment solutions aimed at improving drug stability and compatibility, and contract manufacturing services related to drug packaging and delivery systems. West serves pharmaceutical, biotechnology, and generic drug manufacturers globally, supporting sterile injectable drug administration across a range of therapies.
WST Company Deck
WST Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported a clear top‑ and bottom‑line beat, raised full‑year guidance, and demonstrated margin expansion driven by a favorable mix toward high‑value HVP Components, Biologics and Delivery Devices. Management highlighted operational resilience after a cyber incident, strong growth in Asia Pacific, and continued capital returns. Near‑term headwinds include the cyber incident's effect on West Vantage (pushing revenue into later quarters), operating cash‑flow timing pressure, inflationary costs and FX exposure, and the comparability impact from the SmartDose 3.5 divestiture. Overall, the upside from high‑value product mix, margin gains and raised guidance meaningfully outweigh the discrete and manageable lowlights.View all WST earnings summariesWST Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WST Stock 12 Month Forecast
Average Price Target
$402.75
▲(22.71% Upside)
Technical Analysis
Ownership Overview
0.55% Insiders
26.53% Mutual Funds
2.78% Other Institutional Investors
40.84% Public Companies and
Individual Investors